Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-361 | A-1210477 | Mcl-1 | Misc | Inf | 0.9850 | -0.0083 | 0.0037 | 0.0000 | Inf | -0.045307 |
| MDA-MB-436 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0500 | -0.0343 | -0.0002 | 0.0000 | Inf | -9.0203 |
| MDA-MB-436 | Dasatinib | BCR/ABL | MAPK/nRTK | Inf | 0.6528 | 0.1022 | 0.0098 | 0.0000 | Inf | 0.40773 |
| MDA-MB-436 | A-1210477 | Mcl-1 | Misc | Inf | 0.8728 | 0.0140 | 0.0010 | 0.0000 | Inf | 0.42977 |
| MDA-MB-453 | A-1210477 | Mcl-1 | Misc | Inf | 0.9330 | -0.0364 | 0.0157 | 0.0000 | Inf | -0.33803 |
| MDA-MB-453 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.0309 | 0.8879 | 0.1169 | 0.0000 | Inf | 0.43273 |
| MDA-MB-468 | Palbociclib | CDK4/6 | Cell cycle | Inf | 1.0457 | -0.0214 | 0.0005 | 0.0000 | Inf | -0.58792 |
| SK-BR-3 | ABT-737 | Bcl2/XL | Misc | Inf | 0.9470 | -0.0148 | 0.0045 | 0.0000 | Inf | 0.12804 |
| SUM149PT | TGX221 | PI3Kb | PI3K/mTOR | Inf | 1.0138 | -0.0216 | 0.0006 | 0.0000 | Inf | -4.4171 |
| CAL-51 | A-1210477 | Mcl-1 | Misc | Inf | 0.9919 | 0.0073 | 0.0004 | 0.0000 | Inf | 0.00046652 |
| CAL-51 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.9105 | -0.0094 | 0.0003 | 0.0000 | Inf | 0.56048 |
| MDA-MB-231 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.7110 | 0.2246 | -0.0006 | 0.0000 | Inf | 0.54965 |
| SUM1315MO2 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.4018 | 0.4539 | 0.0330 | 0.0000 | Inf | 0.42807 |
| MDA-MB-231 | Ipatasertib | AKT | PI3K/mTOR | Inf | 0.9254 | 0.0073 | -0.0008 | 0.0000 | Inf | 0.28623 |
| HCC1419 | Everolimus | mTOR1 | PI3K/mTOR | Inf | 0.1803 | 0.7242 | 0.0249 | 0.0000 | Inf | 0.37602 |